LONDON — GSK on Monday said that Luke Miels, the company’s chief commercial officer, will take over as CEO on Jan. 1, replacing Emma Walmsley, who has led the company since 2017.
Walmsley’s tenure included the spinoff of GSK’s consumer health care business into a new firm called Haleon and focusing the company on innovative medicines that could fuel its growth, specifically specialty drugs and certain vaccines.
But investors have questioned the U.K. firm’s strategy at times and whether it’s done enough to position itself to compete into the future, particularly as it loses patent protection on its steady HIV franchise and as it’s faced challenges in its vaccine business. Rival companies have in recent years outpaced GSK, which has seen its shares flatten over the past year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
View All Plans